Drug Trial Radar · NCT04912869
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 26, 2022
Primary completion
Dec 23, 2024
Study completion Aug 15, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD. The primary objective of this study is safety and will additionally evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with placebo.
Conditions
- Sickle Cell Disease
Interventions
CrovalimabDrug
Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
PlaceboDrug
Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs)Time frame: Baseline up to Day 84
- Percentage of Participants with Infusion-Related Reactions and HypersensitivityTime frame: Baseline up to Day 84
Locations
16 sites in 10 countries. Site status is shown where the registry gives one.
Children'S Healthcare of Atlanta
Atlanta, Georgia
Icahn School of Medicine at Mount Sinai
New York, New York
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
CHU Henri Mondor
Créteil, France
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi
Verona, Veneto, Italy
International Cancer Institute (ICI)
Eldoret, Kenya
Gertrude's Children Hospital
Nairobi, Kenya
American University of Beirut - Medical Center
Beirut, Lebanon
Hopital Nini
Tripoli, Lebanon
Amsterdam UMC Location VUMC
Amsterdam, Netherlands
Charlotte Maxeke Johannesburg Hospital
Johannesburg, South Africa
Hospital General Univ. Gregorio Maranon
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.